297-298DOI: 10.17235/reed.2022.8533/2021
17/05/2022 8:27:13 TNG3D
Editorial
Early liver transplantation in severe alcohol-associated hepatitis
DOI: 10.17235/reed.2024.10881/2024
Letter
Strongyloides stercoralis hyperinfection presenting pneumatosis intestinalis and acute respiratory distress syndrome after treatment for COVID-19
DOI: 10.17235/reed.2024.10292/2024
Special Article
Management of liver and gastrointestinal toxicity induced by immune checkpoint inhibitors: Position statement of the AEEH-AEG-SEPD-SEOM-GETECCU
DOI: 10.17235/reed.2024.10250/2024
Fatal HBV-liver failure after withdrawal of antiviral treatment
DOI: 10.17235/reed.2024.10115/2023
Review
Immunogenicity and risk factors for poor humoral immune response to SARS-CoV-2 vaccine in patients with autoimmune hepatitis: a systematic review and meta-analysis
DOI: 10.17235/reed.2024.10053/2023
Original
Screening and risk of hepatocellular carcinoma in patients with advanced fibrosis after hepatitis C virus eradication
DOI: 10.17235/reed.2024.9945/2023
Activity of Spanish gastroenterology units before and after the COVID-19 pandemic: an assessment using the EFIC_AD tool, developed by the Sociedad Española de Patología Digestiva (SEPD)
DOI: 10.17235/reed.2023.9860/2023
Better prognosis of HCV patients diagnosed and treated with an automatic alert system
DOI: 10.17235/reed.2023.9835/2023
Dissemination of the automated alert system in the diagnosis and treatment of hepatitis C
DOI: 10.17235/reed.2023.9801/2023
Drug-induced liver injury associated to red yeast rice
DOI: 10.17235/reed.2023.9797/2023
Is post COVID-19 cholangiopathy an appropriate indication for liver transplantation?
DOI: 10.17235/reed.2023.9740/2023
Fulminant hepatitis due to spontaneous reactivation of virus B in an immunocompetent patient
DOI: 10.17235/reed.2023.9707/2023
Hepatitis B virus reactivation after ibrutinib treatment
DOI: 10.17235/reed.2023.9587/2023
Autoimmune hepatitis after SARS-C¬¬oV-2 vaccination
DOI: 10.17235/reed.2023.9579/2023
Retractions relevant to COVID-19: does the retraction rate jump during the pandemic?
DOI: 10.17235/reed.2023.9549/2023
Reply: SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents
DOI: 10.17235/reed.2023.9438/2022
SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: correspondence
DOI: 10.17235/reed.2023.9347/2022
Oportunistic diagnosis based on age and hepatitis C virus clearance: an essential step to improve the overall health of the liver
DOI: 10.17235/reed.2022.9325/2022
Impact of SARS-CoV-2 vaccination in inflammatory bowel disease patients with different biological agents: a systematic review and meta-analysis
DOI: 10.17235/reed.2022.9264/2022
Hepatitis C virus micro-elimination in vulnerable populations before and during a global pandemic
DOI: 10.17235/reed.2022.9275/2022
Digestive Diseases Image
Endosonographic and ERCP findings in COVID-19 critical illness cholangiopathy
DOI: 10.17235/reed.2022.9218/2022
Ulcerative colitis complicated by autoimmune hepatitis-primary biliary cholangitis-primary sclerosing cholangitis overlap syndrome
DOI: 10.17235/reed.2022.9183/2022
Severe hepatitis E in an immunocompetent young female treated with ribavirin
DOI: 10.17235/reed.2022.9105/2022
Serologic response to COVID-19 vaccines in patients with inflammatory bowel disease: a prospective study
DOI: 10.17235/reed.2022.9101/2022
Protective measures against Omicron could be more effective than Evusheld® in liver transplant recipients
DOI: 10.17235/reed.2022.9058/2022
Current challenges in the functional cure of HBe-Antigen-negative chronic hepatitis B
DOI: 10.17235/reed.2022.9052/2022
New actors come into play against hepatitis delta
DOI: 10.17235/reed.2022.9050/2022
Acute gastrointestinal graft-versus-host disease with cytomegalovirus and Epstein-Barr virus superinfection in a patient with COVID-19
DOI: 10.17235/reed.2022.9001/2022
DRESS syndrome secondary to carbamazepine
DOI: 10.17235/reed.2022.8977/2022
Current state of telemedicine in the field of Hepatology in Spain: challenges, threats and next steps to follow for an intelligent digital transformation
DOI: 10.17235/reed.2022.8918/2022
Acute respiratory failure secondary to megaesophagus: think beyond COVID-19
DOI: 10.17235/reed.2022.8847/2022
Risk of hepatocellular carcinoma in patients with chronic hepatitis c infection and stage 3 fibrosis after sustained virological response
DOI: 10.17235/reed.2022.8840/2022
COVID-19 vaccine and autoimmune hepatitis
DOI: 10.17235/reed.2022.8837/2022
Orthohepevirus C as causal agent of acute hepatitis in Spain
DOI: 10.17235/reed.2022.8993/2022
SARS-CoV-2 vaccine, a new autoimmune hepatitis trigger?
DOI: 10.17235/reed.2022.8820/2022
Cefditoren-induced hepatitis
DOI: 10.17235/reed.2022.8801/2022
Impact of the SARS-CoV-2 pandemic on pancreatic cancer: diagnosis and short-term survival
DOI: 10.17235/reed.2022.8772/2022
Surgical acute abdomen and COVID-19 vaccination
DOI: 10.17235/reed.2022.8721/2022
Acute appendicitis, foreign bodies and COVID-19 vaccination: correspondence
DOI: 10.17235/reed.2022.8671/2022
Health-related quality of life decline in clinically stable inflammatory bowel disease patients during the COVID-19 outbreak
DOI: 10.17235/reed.2022.8668/2022
Hepatitis C virus infection screening reduces mortality and is cost-effective independently of the intervention test
DOI: 10.17235/reed.2022.8609/2022
Outcomes of an automated alert system from Microbiology to link diagnosis to treatment in patients with hepatitis C virus
DOI: 10.17235/reed.2022.8716/2022
A slowdown of hepatitis C diagnosis in high-prevalence groups and with decentralized diagnostic strategies during the COVID-19 pandemic
DOI: 10.17235/reed.2022.8412/2021
A case of COVID-19 with concomitant infection with hepatitis A
DOI: 10.17235/reed.2021.8372/2021
Impact of the COVID-19 pandemic on digestive endoscopists: an Ibero-American study
DOI: 10.17235/reed.2022.8327/2021
Switch to subcutaneous infliximab during the SARS-CoV-2 pandemic: preliminary results
DOI: 10.17235/reed.2021.8320/2021
Cases of liver disease lost in the health system: a call to action
DOI: 10.17235/reed.2021.8316/2021
COVID-19 and aorto-enteric fistula
DOI: 10.17235/reed.2021.8272/2021
Impact of the COVID-19 pandemic on endoscopic retrograde cholangiopancreatography: a single center experience
DOI: 10.17235/reed.2021.8229/2021
Diagnosis of synchronous pancreatic and ampullary adenocarcinomas during the COVID-19 pandemic
DOI: 10.17235/reed.2021.8212/2021
Impact of the COVID-19 lockdown on liver transplant recipients. A single center observational study
DOI: 10.17235/reed.2021.8173/2021
Diagnostic accuracy of circulating microRNA in hepatitis B virus-related hepatocellular carcinoma: a meta-analysis based on Asian data
DOI: 10.17235/reed.2021.8139/2021
Active search for hepatitis C patients in primary care
DOI: 10.17235/reed.2021.8067/2021
Autoimmune hepatitis triggered by COVID-19
DOI: 10.17235/reed.2021.8045/2021
SARS-CoV-2 and splenic infarction: a rarely described thromboembolic presentation
DOI: 10.17235/reed.2021.7964/2021
Assessment of liver damage in patients with COVID-19 is sub-optimal: results of a survey of medical practitioners
DOI: 10.17235/reed.2021.7970/2021
COVID-19 and venous thromboembolism: part of a multisystem disease
DOI: 10.17235/reed.2021.7907/2021
Pneumoperitoneum and COVID-19. A causal association?
DOI: 10.17235/reed.2021.7877/2021
COVID-19 and the liver: the chicken or the egg dilemma
DOI: 10.17235/reed.2021.7861/2021
Pneumatosis intestinalis as an incidental finding in a patient with COVID-19 infection
DOI: 10.17235/reed.2021.7857/2021
Abnormal liver chemistry constitutes an independent prognostic factor of less favorable clinical course in patients with COVID-19
DOI: 10.17235/reed.2021.7842/2021
Experience in the treatment of hepatitis C with direct-acting antivirals in a foreign population at a high-immigration area
DOI: 10.17235/reed.2021.7830/2021
Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience
DOI: 10.17235/reed.2021.7829/2021
Telemedicine, time to change the paradigm of hepatitis C management: improve access and reduce costs In reference to: Chronic viral hepatitis C micro-elimination program using telemedicine. The Mexican experience, by Pérez Hernández et al.
DOI: 10.17235/reed.2021.7809/2021
Pancreatic injury and acute pancreatitis in COVID-19 patients
DOI: 10.17235/reed.2021.7807/2021
Emphysematous hepatitis: a very rare entity with a poor prognosis
DOI: 10.17235/reed.2021.7795/2021
Influence of the onset of the SARS-CoV-2 pandemic on the diagnosis and treatment of ulcerative colitis
DOI: 10.17235/reed.2021.7768/2020
COVID-19 and the digestive system: implications for transforming care delivery
DOI: 10.17235/reed.2021.7774/2020
The COVID-19 pandemic shows us in which way the care of patients with inflammatory bowel disease should move
DOI: 10.17235/reed.2021.7765/2020
Risk of COVID-19 transmission in esophageal, anorectal manometry and 24-hour impedance-pH monitoring
DOI: 10.17235/reed.2021.7767/2020
Safety in digestive endoscopy during the ongoing COVID-19 pandemic
DOI: 10.17235/reed.2021.7748/2020
Hepatitis C in homeless people: reaching a hard-to-reach population
DOI: 10.17235/reed.2021.7737/2020
The Screening Guidelines for Hepatitis C Virus Infection as a milestone in the path towards hepatitis C virus elimination
DOI: 10.17235/reed.2021.7736/2020
Screening guide for hepatitis C virus infection in Spain
DOI: 10.17235/reed.2020.7728/2020
Leading in turbulent times with the aim to serve
DOI: 10.17235/reed.2020.7684/2020
Resumption of endoscopy in the Galician colorectal cancer screening programme after the COVID-19 lock down: patient safety results
DOI: 10.17235/reed.2020.7647/2020
Poor agreement between clinical screening and universal pre-procedure SARS-CoV-2 PCR testing prior to endoscopy
DOI: 10.17235/reed.2021.7612/2020
Spontaneous pneumoperitoneum and pneumatosis intestinalis as sole manifestations of a COVID-19 infection. An extremely rare complication
DOI: 10.17235/reed.2020.7601/2020
Patients with upper gastrointestinal foreign bodies are more likely to consult later and with a higher rate of hospitalization during the COVID-19 pandemic
DOI: 10.17235/reed.2020.7593/2020
Chronic hepatitis C patients lost in the system: predictive factors of non-referral or loss of follow-up in Hepatology units
DOI: 10.17235/reed.2020.7573/2020
Adherence to intravenous biological treatment in inflammatory bowel disease patients during the COVID-19 pandemic
DOI: 10.17235/reed.2020.7562/2020
Pancreatic injury in COVID-19: pathogenesis and challenges
DOI: 10.17235/reed.2020.7541/2020
Consequences and management of COVID-19 on the care activity of an Inflammatory Bowel Disease Unit
DOI: 10.17235/reed.2020.7543/2020
SARS-CoV-2 and acute pancreatitis: a new etiological agent?
DOI: 10.17235/reed.2020.7481/2020
Views of patients with inflammatory bowel disease during the COVID-19 pandemic: ACCU survey results
DOI: 10.17235/reed.2020.7472/2020
The impact of SARS-CoV-2 infection on the surgical management of colorectal cancer: lessons learned from a multicenter study in Spain
DOI: 10.17235/reed.2020.7460/2020
Pre-procedural antibody testing for SARS-CoV-2 in the routine endoscopic practice
DOI: 10.17235/reed.2020.7434/2020
Latin American authorship in scientific production on COVID-19
DOI: 10.17235/reed.2020.7432/2020
DOI: 10.17235/reed.2020.7425/2020
Impact of liver injury on the severity of COVID-19: a systematic review with meta-analysis
DOI: 10.17235/reed.2020.7397/2020
Autoimmune hepatitis, primary sclerosing cholangitis, and inflammatory bowel disease. Sequential overlap syndrome: a twist to the mosaic of autoimmunity
DOI: 10.17235/reed.2020.7512/2020
Evaluation of endoscopy requests in the resumption of activity during the SARS-CoV-2 pandemic: denial of nonindicated requests and prioritization of accepted requests
DOI: 10.17235/reed.2020.7375/2020
Severe colon ischemia in patients with severe coronavirus-19 (COVID-19)
DOI: 10.17235/reed.2020.7329/2020
COVID-19. Immunothrombosis and the gastrointestinal tract
DOI: 10.17235/reed.2020.7292/2020
Prevalence of hepatitis C in patients with non-affective psychotic disorders
DOI: 10.17235/reed.2020.7278/2020
Acute hepatocellular drug-induced liver injury probably caused by doxazosin
DOI: 10.17235/reed.2020.7268/2020
Ribavirin monotherapy for the treatment of chronic hepatitis E in an immunosuppressed patient
DOI: 10.17235/reed.2020.7266/2020
Alcoholic-related liver disease: pathogenesis, management and future therapeutic developments
DOI: 10.17235/reed.2020.7242/2020
Acute hepatitis due to olmesartan: an uncommon entity
DOI: 10.17235/reed.2020.7236/2020
Linkage to care strategy for the micro-elimination of hepatitis C among parenteral drug users on methadone replacement therapy in Gipuzkoa
DOI: 10.17235/reed.2020.7194/2020
Author´s answer to: “Effect of adacolumn® in ulcerative colitis with COVID-19”
DOI: 10.17235/reed.2020.7188/2020
The effect of Adacolumn® on ulcerative colitis with COVID-19
DOI: 10.17235/reed.2020.7156/2020
COVID-19 and the digestive system: protection and management during the SARS-CoV-2 pandemic
DOI: 10.17235/reed.2020.7128/2020
Strategy for the Elimination of Hepatitis C in Cantabria
DOI: 10.17235/reed.2020.7108/2020
Reflex testing. A key tool for the elimination of hepatitis C
DOI: 10.17235/reed.2020.7201/2020
Hepatitis C and beta-thalassemia major in children: experience with glecaprevir/pibrentasvir
DOI: 10.17235/reed.2020.7092/2020
Patients with hepatitis C lost to follow-up: ethical-legal aspects and search results
DOI: 10.17235/reed.2020.7077/2020
Changes in the characteristics of hospital admissions due to decompensated cirrhosis in the era of direct-acting antivirals against hepatitis C virus
DOI: 10.17235/reed.2020.7024/2020
Prevalence and detection of undiagnosed active hepatitis C virus infections in Navarre, Spain, 2017-2019
DOI: 10.17235/reed.2020.7000/2020
Candesartan-induced cholestatic hepatitis: a case report
DOI: 10.17235/reed.2020.6988/2020
Diabetes is not associated with an increased risk of hepatocellular carcinoma in patients with alcoholic or hepatitis C virus cirrhosis
DOI: 10.17235/reed.2020.6953/2020
Recapture of patients with an incomplete diagnosis of hepatitis C virus infection
DOI: 10.17235/reed.2020.6944/2020
Autoimmune sequential overlap syndrome (autoimmune hepatitis/primary sclerosing cholangitis) and inflammatory bowel disease: three clinical cases
DOI: 10.17235/reed.2020.6938/2020
Review of hepatitis C screening programs for immigrants in Spain from endemic countries
DOI: 10.17235/reed.2020.6916/2020
Spontaneous clearance of chronic hepatitis C in an immunocompetent patient
DOI: 10.17235/reed.2020.6909/2020
Effective treatment of autoimmune hepatitis-primary biliary cholangitis overlap syndrome with obeticholic acid
DOI: 10.17235/reed.2020.6883/2020
The development of type-1 autoimmune hepatitis after chronic hepatitis C (HCV) clearance by direct-acting antivirals (DAA)
DOI: 10.17235/reed.2020.6785/2019
Principles for implementing a population screening strategy for hepatitis C in Spain
DOI: 10.17235/reed.2019.6768/2019
Efficacy of entecavir in treating hepatitis B virus-associated membranous nephropathy
DOI: 10.17235/reed.2020.6762/2019
Elimination of hepatitis C. Positioning document of the Spanish Association for the Study of the Liver (AEEH)
DOI: 10.17235/reed.2019.6700/2019
Sexual behaviour and poor hygiene are related to recent hepatitis a virus community outbreaks
DOI: 10.17235/reed.2020.6687/2019
Metabolic syndrome, non-alcoholic fatty liver disease and hepatocarcinoma
DOI: 10.17235/reed.2020.6640/2019
The relationship between integrin avß6 and HBV infection in patients with liver cirrhosis and hepatocellular carcinoma: a preliminary report
DOI: 10.17235/reed.2020.6607/2019
A new pattern in hepatitis A virus infection in an urban population
DOI: 10.17235/reed.2020.6526/2019
Successful evolution of morphea after hepatitis C virus eradication with direct-acting antiviral agent treatment
DOI: 10.17235/reed.2019.6461/2019
Towards the elimination of hepatitis C: implementation of reflex testing in Andalusia
DOI: 10.17235/reed.2020.6370/2019
Quality of life study in asymptomatic patients with hepatitis C
DOI: 10.17235/reed.2019.6339/2019
Definition of the profiles of hepatitis C virus patients based on the identification of risky practices in Spain
DOI: 10.17235/reed.2019.6169/2019
The contribution of telemedicine to hepatitis C elimination in a correctional facility
DOI: 10.17235/reed.2019.6152/2018
Geographic analysis and estimation of hepatitis C cases in migrant populations living in Spain: is a country-based screening strategy appropriate?
DOI: 10.17235/reed.2019.6117/2018
Analysis of the burden and variability in the management of NAFLD patients in the clinical practice: unifying the required criteria
DOI: 10.17235/reed.2019.6088/2018
Long-term changes on health-related quality of life in patients with chronic hepatitis C after viral clearance with direct-acting antiviral agents
DOI: 10.17235/reed.2019.6063/2018
Case Report
Leukocytoclastic vasculitis after vaccination in a patient with inflammatory bowel disease
DOI: 10.17235/reed.2019.5963/2018
An assessment of bacterial overgrowth and translocation in the non-alcoholic fatty liver of patients with morbid obesity
DOI: 10.17235/reed.2019.5942/2018
Acute seronegative hepatitis C: two case reports
DOI: 10.17235/reed.2019.5921/2018
The efficiency of several one-step testing strategies for the diagnosis of hepatitis C
DOI: 10.17235/reed.2018.5810/2018
An outbreak of acute hepatitis due to the hepatitis A virus in 2017: are we witnessing a change in contagion risk factors?
DOI: 10.17235/reed.2018.5633/2018
Economic evaluation of a population strategy for the treatment of chronic hepatitis C with direct-acting antivirals
DOI: 10.17235/reed.2018.5605/2018
Sarcoidosis onset simulating a unique hepatic metastasis
DOI: 10.17235/reed.2018.5553/2018
Healing of autoimmune hepatitis associated with hepatitis C virus infection treated with direct-acting antivirals
DOI: 10.17235/reed.2018.5528/2018
Hepatitis E virus in neurological disorders: a case of Parsonage-Turner syndrome
DOI: 10.17235/reed.2018.5506/2018
Disruptive therapeutic innovation and the opportunity to eliminate a chronic disease – The issue of chronic hepatitis C in Spain
DOI: 10.17235/reed.2017.5384/2017
Letter to the Editor
Autoimmune hepatitis as a complication of common variable immunodeficiency
DOI: 10.17235/reed.2018.5280/2017
Effectiveness of direct-acting antiviral therapy in patients with a HCV/HIV coinfection. A multicenter cohort study
DOI: 10.17235/reed.2017.5210/2017
Outbreak of acute hepatitis A in the health area served by the Hospital Universitario Virgen de la Victoria (HUVV): a change in epidemiology
DOI: 10.17235/reed.2018.5207/2017
Liver transplantation in hemophilia A and von Willebrand disease type 3: perioperative management and post-transplant outcome
DOI: 10.17235/reed.2018.5204/2017
Value and innovation of direct-acting antivirals: long-term health outcomes of the strategic plan for the management of hepatitis C in Spain
DOI: 10.17235/reed.2017.5063/2017
Hepatitis with a multiple etiology in HIV-positive men who have sexual relations with other men
DOI: 10.17235/reed.2017.5033/2017
Nonalcoholic steatohepatitis and hepatic adenomatosis: casual or causal relationship?
DOI: 10.17235/reed.2017.4981/2017
Insulin resistance and the metabolic syndrome are related to the severity of steatosis in the pediatric population with obesity
DOI: 10.17235/reed.2017.4898/2017
Liver metastasis from neuroendocrine carcinoma after the use of the new direct-action antivirals against hepatitis C virus in a patient with past history of hepatocellular carcinoma
DOI: 10.17235/reed.2017.4772/2016
Cost-effectiveness of a hepatitis B virus screening strategy to prevent reactivation in patients with hematologic neoplasms
DOI: 10.17235/reed.2017.4693/2016
Serum thymosin beta4 as a noninvasive biomarker in patients with nonalcoholic steatohepatitis
DOI: 10.17235/reed.2017.4690/2016
Hepatocellular carcinoma in patients without advanced fibrosis after HCV eradication antiviral treatment
DOI: 10.17235/reed.2017.4677/2016
The clinical challenge of chronic Q fever with isolated liver involvement
DOI: 10.17235/reed.2017.4633/2016
Hepatocellular carcinoma presenting with Budd-Chiari syndrome, right atrial thrombus and pulmonary emboli
Could viral load combined with indirect serum markers be an option for predicting the degree of liver fibrosis in treatment-naïve chronic hepatitis B patients?
DOI: 10.17235/reed.2016.4439/2016
Methylation status of the estrogen receptor 1 promoter predicts poor prognosis of acute-on-chronic hepatitis B liver failure
DOI: 10.17235/reed.2017.4426/2016
Autochthonous acute hepatitis E: an increasingly frequent diagnosis. Clinical-epidemiological analysis of our experience
DOI: 10.17235/reed.2017.4258/2016
The clinical extremes of autoimmune cholangitis
DOI: 10.17235/reed.2017.4167/2015
Severe acute hepatitis and cold agglutinin-related hemolytic anemia secondary to prime infection with Epstein-Barr virus
DOI: 10.17235/reed.2017.4072/2015
HBsAg seroclearance or seroconversion induced by peg-interferon alpha and lamivudine or adefovir combination therapy in chronic hepatitis B treatment: a meta-analysis and systematic review
DOI: 10.17235/reed.2016.3995/2015
Glycogenic hepatopathy in young adults: a case series
DOI: 10.17235/reed.2016.3934/2015
Causes of treatment failure for hepatitis C in the era of direct-acting antiviral therapy
DOI: 10.17235/reed.2015.3894/2015
The diagnostic value of a globulin/platelet model for evaluating liver fibrosis in chronic hepatitis B patients
DOI: 10.17235/reed.2015.3851/2015
Efficacy and safety of simeprevir in combination with peginterferon and ribavirin for patients with hepatitis C genotype 1 infection: A meta-analysis of randomized trials
DOI: 10.17235/reed.2015.3840/2015
Anal Intraepithelial neoplasia: A narrative review
DOI: 10.17235/reed.2015.3788/2015
Download the citation for this article by clicking on one of the following citation managers:
Received: 17/12/2021
Accepted: 05/01/2022
Online First: 18/01/2022
Published: 06/05/2022
Article Online First time: 32 days
Article editing time: 140 days
Submission and tracking
Access to the information published on the website (www.reed.es) of the Sociedad Española de Patología Digestiva (SEPD), Calle Sancho Dávila, 6, 28028 Madrid, CIF: G28486280, telephone: 914021353, e-mail: sepd@sepd.es, implies acceptance of the following conditions of use:
1. The SEPD published its website in order to make it easier for potential visitors to access information related to its services. The information displayed on this website is made available to users accessing the website, both privately and individually, at no additional cost. The commercialization of access rights is expressly prohibited.
2. It is expressly forbidden to copy or reproduce the information published by means of any electronic medium (web pages, databases, web pages or electronic publications) that allows the dissemination of any information published on this website to multiple users without the prior written consent of the SEPD.
3. Accuracy of information: The SEPD endeavors to display accurate and up-to-date information on its website. However, the SEPD is not responsible for the consequences of reading this information.
4. SEPD is not liable for any damages that the user may cause in connection with access to this website or the use of its contents.
5. Notice to users and/or patients: The information included in www.reed.es is for the exclusive use of healthcare professionals and this will be stated in the registration and access alert.
6. Funding: REED, the official scientific body of the EDPS, shares the same sources of funding as the EDPS, as laid down in Article 22, SECTION VII (ECONOMIC AND DOCUMENTARY SYSTEM) of the EDPS's Statutes.
The website http://www.reed.es may host advertising from third parties that may be considered of interest to the user and in no way a source of budgetary funding for the website. Wherever the word 'Advertising' is displayed, it will be highlighted.
However, advertising that infringes Law 29/2006 on guarantees and rational use of medicines and health products will not be accepted. Likewise, there will be no advertising of any kind in those areas of the website where there may be a conflict of interest.
Advertisers have no rights over their editorial content.
7. Access to restricted areas: In relation to access to restricted areas where the user voluntarily completes the registration form, the EDPS will assign the user a password which will be sent to the e-mail address provided by the user, who must make diligent use of the password and keep it secret. Consequently, the user accepts that he/she is responsible for the correct custody and confidentiality of the password/identifier provided by the EDPS. Furthermore, the user shall not provide access to third parties, either temporarily or permanently, or allow access to third parties.
Consequently, the user is solely responsible for all accesses, contents and actions he/she carries out in connection with his/her user ID and access code, with full indemnity for the EDPS.
On this basis, the user is responsible for immediately informing the EDPS of any factors that allow the misuse of the IDs and/or passwords, such as theft, loss or unauthorized access, in order to cancel them immediately. Until such incidents are reported, SEPD will not be liable for any liability that may arise from the misuse of identifiers or passwords by unauthorized third parties.
The user understands and accepts that he/she is accessing a website with content intended exclusively for medical staff and acknowledges that he/she is a healthcare professional.
Notes of interest to members and visitors to the EDPS website: The data and information contained in all content on these websites are only guidance documents for members and are therefore not legally binding.
8. License for public use of the website: is governed by Spanish law, regardless of the country in which the user accesses the website. Any controversy that may arise in the interpretation of these rules of access will be resolved before the Spanish Courts and Tribunals.
Copyright and Creative Commons POR NC ND: The total or partial reproduction of texts and graphics by any means is prohibited without the express written authorization of the EDPS. To insert these texts, images or news items in the publication or dissemination in any medium of any kind accessible to third parties, the express written consent of the EDPS must be obtained.
The private use of the texts, news and data published on this website is strictly for personal purposes.
The General Data Protection Regulation (Regulation (EU) 2016/679) harmonizes Data Protection legislation across the European Union, increasing the protection of individuals and giving them greater control over their personal data.
At the Spanish Society of Digestive Pathology (SEPD), we have always been concerned about the protection of personal data. We have therefore updated our Privacy Policy in order to bring it into line with the new regulations and to inform you of the changes that affect your rights:
Responsible for the processing of your personal data: SOCIEDAD ESPAÑOLA DE PATOLOGÍA DIGESTIVA (SEPD), CIF: G28486280 and registered office at Calle Sancho Dávila 6, 28028 Madrid.
The data collected by the Sociedad Española de Patología Digestiva (SEPD) are obtained in different ways (website, e-mail, electronic forms or on paper) through its activity as a business association and service provider; these data will become part of an information file for which it is responsible.
Purpose of data collection:
Legitimacy of the processing:
Recipients of the data.
Data subjects:
Everyone can know whether or not the EDPS processes their personal data. They have the right to:
SEPD will cease to process the data, except for legitimate reasons, or for the exercise or defense of possible claims.
Origin of the data: SEPD will obtain personal data directly from the data subject through the following communication channels:
Categories of data:
Sending of commercial communications: In accordance with the LSSI, Law 34/2002, and Law 29/2009, of 30 December, if you do not wish to receive any more commercial communications, please send an e-mail with the word BAJA (unsubscribe) to the following address: sepd@sepd.es.
Security measures: SEPD informs that it has adopted all necessary security measures to prevent theft, alteration or unauthorized access to data, taking into account the state of the art, the costs of implementation, the nature, scope, context and purpose of the processing, as well as the variable risks of probability and severity to the rights and freedoms of individuals, such as in cases of outsourced services, request and ensure that the controller implements appropriate technical and organizational measures to ensure an adequate level of security against existing threats, as stated in art. 32 of the Data Protection Regulation.
Exercise of rights:
Everyone has the right to know whether the EDPS processes his or her personal data. He or she also has the right to:
Access their personal data,
Request the rectification of inaccurate data.
Request deletion when, among other reasons, the data are no longer necessary for the purposes for which they were collected.
Object to the processing of your data, on grounds relating to your particular situation, by requesting that they not be processed by the EDPS.
In certain circumstances, request the restriction of the processing of your data, in which case they will only be kept for the exercise or defense of claims.
Withdraw, at any time, the consent given, without this affecting the lawfulness of the processing that we have carried out prior to such withdrawal.
The interested party may exercise their rights at the following address: Sociedad Española de Patología Digestiva (SEPD), c/ Calle Sancho Dávila, 6 28028 Madrid, or by email to the following address: sepd@sepd.es, any controversy that may arise in the interpretation of these access rules will be resolved before the Spanish Courts and Tribunals.
Remember that whenever you exercise any of the rights set out above, you must accompany your request with a copy of your ID card or equivalent document that allows us to verify your identity.
Likewise, if you are not satisfied with how we have dealt with your rights, you may file a complaint with the Spanish Data Protection Agency, through the website www.aepd.es.
The following table describes in detail the cookies present on the website
The user has also been informed of the cookies used by this website by means of the banner that appears on the home screen during the first browsing visit to this website, in which the user can configure them at their own discretion, requesting their consent and management.
A cookie is a small piece of information, usually a few kilobytes to several megabytes in size, which is stored on your terminal when you visit our website. The cookie is used to remember your preferences and other information about your browsing history of our website.
Cookies can be first-party or third-party cookies. This varies depending on whether the cookies are sent to your terminal from a computer or domain managed by us (own cookies), or are sent from a computer or domain not managed by us (third party cookies). They can remain active from a few minutes to several years, or only during the session.
Cookies can have many purposes and sometimes several are grouped together. In addition, there is a group of technical cookies that are necessary for the proper functioning of website, being mandatory to obtain consent for the rest of the cookies with different purposes. Depending on their purpose we can distinguish,
If you wish, you can also manage cookies through your browser. Most browsers are set by default to accept cookies, but you can change the settings to block, delete and manage some or all cookies if you prefer. Please be aware of the possible changes that can occur when deleting or blocking cookies.
Chrome:
https://support.google.com/chrome/answer/95647?hl=es
Explorer:
https://support.microsoft.com/es-es/topic/eliminar-y-administrar-cookies-168dab11-0753-043d-7c16-ede5947fc64d
Edge:
https://support.microsoft.com/es-es/microsoft-edge/eliminar-las-cookies-en-microsoft-edge-63947406-40ac-c3b8-57b9-2a946a29ae09
Safari:
- Ipad, Iphone, Ipod Touch: https://support.apple.com/es-es/HT201265
- Mac: Preferencias, Panel de privacidad
Firefox:
https://support.mozilla.org/es/kb/Borrar%20cookies